Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Persistence of antibodies induced by measles-mumps-rubella vaccine in children in India.

Literature DB >> 17699834

Persistence of antibodies induced by measles-mumps-rubella vaccine in children in India.

S K Raut¹, P S Kulkarni, M A Phadke, S S Jadhav, S V Kapre, R M Dhere, S P Dhorje, S R Godse.

Abstract

Antibody levels in 41 Indian girls were measured 6 years after measles-mumps-rubella (MMR) vaccination. Rates of seropositivity were 88% (measles antibodies), 95% (mumps antibodies), and 100% (rubella antibodies). The MMR vaccine induces long-term immunity in a majority of vaccinees; however, due to the observation of some seronegative vaccinees, the policy of administering a second dose of the MMR vaccine seems appropriate.

Entities: Disease Species

Mesh：

Substances：

Year: 2007 PMID： 17699834 PMCID： PMC2168128 DOI： 10.1128/CVI.00246-07

Source DB: PubMed Journal: Clin Vaccine Immunol ISSN： 1556-679X

13 in total

1. Neutralization activity and persistence of antibodies induced in response to vaccination with a novel mumps strain, RIT 4385.

Authors: V Usonis; V Bakasenas; M Denis
Journal: Infection Date: 2001 May-Jun Impact factor: 3.553

2. A limited measles outbreak in a highly vaccinated US boarding school.

Authors: Lorraine F Yeung; Perrianne Lurie; Gustavo Dayan; Eduard Eduardo; Phyllis H Britz; Susan B Redd; Mark J Papania; Jane F Seward
Journal: Pediatrics Date: 2005-12 Impact factor: 7.124

Review 3. Duration of live measles vaccine-induced immunity.

Authors: L E Markowitz; S R Preblud; P E Fine; W A Orenstein
Journal: Pediatr Infect Dis J Date: 1990-02 Impact factor: 2.129

4. Immunogenicity and reactogenicity of indigenously produced MMR vaccine.

Authors: I Bhargava; B C Chhaparwal; M A Phadke; S F Irani; D Chhaparwal; S Dhorje; C P Maheshwari
Journal: Indian Pediatr Date: 1995-09 Impact factor: 1.411

5. Measles, mumps, and rubella antibodies in children 5-6 years after immunization: effect of vaccine type and age at vaccination.

Authors: N Boulianne; G De Serres; S Ratnam; B J Ward; J R Joly; B Duval
Journal: Vaccine Date: 1995-11 Impact factor: 3.641

6. Sustained transmission of mumps in a highly vaccinated population: assessment of primary vaccine failure and waning vaccine-induced immunity.

Authors: P A Briss; L J Fehrs; R A Parker; P F Wright; E C Sannella; R H Hutcheson; W Schaffner
Journal: J Infect Dis Date: 1994-01 Impact factor: 5.226

7. Outbreak of mumps in a vaccinated child population: a question of vaccine failure?

Authors: Corinne Vandermeulen; Mathieu Roelants; Marijke Vermoere; Katelijn Roseeuw; Patrick Goubau; Karel Hoppenbrouwers
Journal: Vaccine Date: 2004-07-29 Impact factor: 3.641

8. Comparative evaluation of measles, mumps & rubella vaccine at 9 & 15 months of age.

Authors: Sangita Yadav; Richa Thukral; Anita Chakarvarti
Journal: Indian J Med Res Date: 2003-11 Impact factor: 2.375

9. Explosive school-based measles outbreak: intense exposure may have resulted in high risk, even among revaccinees.

Authors: M Paunio; H Peltola; M Valle; I Davidkin; M Virtanen; O P Heinonen
Journal: Am J Epidemiol Date: 1998-12-01 Impact factor: 4.897

10. Measles, mumps, and rubella--vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP).

Authors: J C Watson; S C Hadler; C A Dykewicz; S Reef; L Phillips
Journal: MMWR Recomm Rep Date: 1998-05-22

7 in total

1. Persistence and titer changes of rubella virus antibodies in primiparous women who had been vaccinated with strain RA 27/3 in junior high school.

Authors: Ching-Chiang Lin; Chun-Yuh Yang; Yung-Luen Shih; Yang-Yang Huang; Tsung-Han Yang; Jin-Yuan Liang; Chu-Fen Chang; Hsiu-Shu Hsieh; Yeou-Lih Huang
Journal: Clin Vaccine Immunol Date: 2011-11-09

Persistence of antibodies induced by measles-mumps-rubella vaccine in children in India.

1. Neutralization activity and persistence of antibodies induced in response to vaccination with a novel mumps strain, RIT 4385.

2. A limited measles outbreak in a highly vaccinated US boarding school.

Review 3. Duration of live measles vaccine-induced immunity.

4. Immunogenicity and reactogenicity of indigenously produced MMR vaccine.

5. Measles, mumps, and rubella antibodies in children 5-6 years after immunization: effect of vaccine type and age at vaccination.

6. Sustained transmission of mumps in a highly vaccinated population: assessment of primary vaccine failure and waning vaccine-induced immunity.

7. Outbreak of mumps in a vaccinated child population: a question of vaccine failure?

8. Comparative evaluation of measles, mumps & rubella vaccine at 9 & 15 months of age.

9. Explosive school-based measles outbreak: intense exposure may have resulted in high risk, even among revaccinees.

10. Measles, mumps, and rubella--vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP).

1. Persistence and titer changes of rubella virus antibodies in primiparous women who had been vaccinated with strain RA 27/3 in junior high school.

2. MMR Vaccine and Covid-19: A Myth or a Low Risk-High Reward Preventive Measure?

3. An infant with congenital rubella syndrome in developing India.

4. Update on available vaccines in India: report of the APPA VU 2010: I.

5. Low rate of seropositivity (IgG) to mumps component in MMR vaccinees in Chennai, south India.

6. Measles in India: Challenges & recent developments.

7. Viral Vaccines in India: An Overview.